Celularity Stock Today
| CELUW Stock | USD 0.07 0.01 16.28% |
PerformanceGood
| Odds Of DistressQuite High
|
Celularity is selling for under 0.07 as of the 17th of March 2025; that is 16.28 percent increase since the beginning of the trading day. The stock's lowest day price was 0.0602. Celularity has more than 65 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of July 2019 | Category Healthcare | Classification Health Care |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. More on Celularity
Moving together with Celularity Stock
Moving against Celularity Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Celularity Stock Highlights
| President Diseases | Stephen DPM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celularity can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Celularity's financial leverage. It provides some insight into what part of Celularity's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celularity (CELUW) is traded on NASDAQ Exchange in USA. It is located in 170 Park Avenue, Florham Park, NJ, United States, 07932 and employs 120 people. Celularity is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Celularity has accumulated about 38 M in cash with (38.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Celularity Probability Of Bankruptcy
Celularity Historical Income Statement
Celularity Stock Against Markets
Celularity Corporate Management
| Carlos Ramirez | SVP Relations | Profile | |
| Sharmila MD | Senior Safety | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Tim Wilk | Senior Operations | Profile | |
| Ramji Krishnan | Chief Officer | Profile | |
| Bradley Glover | Ex COO | Profile | |
| CPA MS | Treasurer | Profile |
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.